Ensifentrine
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.
Journal: Seminars in respiratory and critical care medicine
Published: March 17, 2026
Ensifentrine, a novel dual phosphodiesterase 3 and 4 inhibitor in the treatment of chronic obstructive pulmonary disease.
Journal: JPMA. The Journal of the Pakistan Medical Association
Published: February 25, 2026
Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease.
Journal: International journal of chronic obstructive pulmonary disease
Published: December 23, 2025
Ensifentrine: A Potential Shift in COPD Management.
Journal: JPMA. The Journal of the Pakistan Medical Association
Published: December 11, 2025
Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder.
Journal: The Annals of pharmacotherapy
Published: November 05, 2025
Efficacy and Safety of Ensifentrine in Chinese Patients with Chronic Obstructive Pulmonary Disease: The ENHANCE-CHINA Randomized Clinical Trial.
Journal: Chest
Published: October 15, 2025
Hydrophobic interaction-driven binding of ensifentrine stabilizes PDE3A: insights from X-ray crystallography and molecular dynamics.
Journal: Physical chemistry chemical physics : PCCP
Published: October 10, 2025
Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast.
Journal: Pulmonary therapy
Published: September 12, 2025
Anti-oxidative and anti-inflammatory effects of the phosphodiesterase 3/4 inhibitor ensifentrine.
Journal: International immunopharmacology
Published: August 12, 2025
Anti-inflammatory agents for the management of COPD - Quo Vadis?
Journal: Respiratory medicine
Published: July 26, 2025
Last Updated: 04/28/2026